Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 141.82M P/E - EPS this Y - Ern Qtrly Grth -
Income -845.61M Forward P/E -1.50 EPS next Y - 50D Avg Chg -11.00%
Sales 13.15M PEG - EPS past 5Y - 200D Avg Chg -37.00%
Dividend N/A Price/Book 0.81 EPS next 5Y 57.80% 52W High Chg -95.00%
Recommedations 4.00 Quick Ratio 1.65 Shares Outstanding 34.95M 52W Low Chg 2.00%
Insider Own - ROA -88.16% Shares Float 28.15M Beta 0.70
Inst Own 2.16% ROE -251.34% Shares Shorted/Prior 1.21M/300.55K Price 3.86
Gross Margin 100.00% Profit Margin - Avg. Volume 3,735,478 Target Price 1.00
Oper. Margin -5,922.12% Earnings Date - Volume 616,747 Change -1.78%
Orphazyme A/S News
10/14/21 50 Biggest Movers From Yesterday
10/07/21 Modified long-term share-based incentive program for 2021
10/05/21 The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
10/05/21 Orphazyme provides regulatory and financial updates
09/07/21 DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Orphazyme A/S and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
09/07/21 ORPH Final Deadline Today: Rosen, Leading Trial Attorneys, Encourages Orphazyme A/S Investors with Losses in Excess of $100K to Secure Counsel Before Important September 7 Deadline in Securities Class Action - ORPH
09/07/21 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orphazyme, CorMedix, Koninklijke Philips, and Sesen Bio and Encourages Investors to Contact the Firm
09/06/21 DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Orphazyme A/S and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
09/06/21 Final Deadline for Investors with Losses Exceeding $500K to Actively Participate in the Orphazyme A/S (ORPH) Class Action - Bronstein, Gewirtz & Grossman, LLC
09/06/21 ORPH Final Deadline Tomorrow: Rosen, Top Ranked Global Counsel, Encourages Orphazyme A/S Investors with Losses to Secure Counsel Before Important September 7 Deadline in Securities Class Action - ORPH
09/05/21 ORPH FINAL DEADLINE ALERT: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Orphazyme A/S Investors with Losses to Secure Counsel Before Important September 7 Deadline in Securities Class Action – ORPH
09/05/21 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Orphazyme A/S of Class Action Lawsuit and Upcoming Deadline - ORPH
09/03/21 The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Orphazyme A/S (ORPH)
09/03/21 Last Few Days for Investors with Losses Exceeding $500K to Actively Participate in the Orphazyme A/S (ORPH) Class Action - Bronstein, Gewirtz & Grossman, LLC
09/03/21 TUESDAY DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Orphazyme A/S and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
09/02/21 TUESDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Orphazyme A/S and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
09/01/21 DEADLINE ALERT for ORPH, YMM, BZ, QFIN: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
09/01/21 Upcoming ORPH Deadline: Investors with Losses Exceeding $500K Are Encouraged to Actively Participate in the Orphazyme A/S Class Action - Bronstein, Gewirtz & Grossman, LLC
09/01/21 TUESDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Orphazyme A/S and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.

ORPH Chatroom

User Image Slowtime Posted - 1 hour ago

$ORPH Any day now boys!

User Image Kikimora35 Posted - 1 hour ago

$ORPH bullish tomorrow show this corrupted market how’s move up

User Image GordonPaton Posted - 4 hours ago

$IFRX $ORPH spiked to $70 due to low float.

User Image ManInTheMirror Posted - 5 hours ago

$ORPH that 10.00 area is where I see price filling.. it keeps faking everyone out, needs people to sell before it can really run. But I like the way it's acting lately, hopefully we stay above this ATL

User Image WhiskeyThrottle Posted - 5 hours ago

$ORPH lol. I down so far on this it’s just entertaining. It either turns around or goes to zero. No point selling now 😂

User Image miracleboy Posted - 7 hours ago

$ORPH are shorts planning to feast on stock offering if it happens.

User Image Sandy001 Posted - 7 hours ago

$ORPH

User Image B3B3Stk Posted - 8 hours ago

$CRTX reminds me of $RCON & $ORPH look at where those two are now. This will not recover anytime soon.

User Image FunToFomo Posted - 9 hours ago

$ORPH just bought another 109 shares let’s gooooooooooo

User Image tickeron Posted - 9 hours ago

How do you think the market will react to this? $ORPH enters a Downtrend as Momentum Indicator dropped below the 0 level on October 26, 2021. View odds for this and other indicators: https://srnk.us/go/3125282

User Image Avocado_smash Posted - 9 hours ago

$ORPH F-3 Shelf filling on 10/15 already in effect per 10/22. Company can sell anytime when the price is favorable. nice ! https://investors.orphazyme.com/static-files/c3a6a37d-3234-4279-bf47-44ff50b00dc1

User Image Avocado_smash Posted - 9 hours ago

$ORPH Assuming they held the meeting on Oct 15th , then we will have the PR any day now regarding the FDA feedback either in good way or bad way. Def risky but it will payoff if you are in the right boat.

User Image MiraMora Posted - 10 hours ago

$ORPH shib coin…if you want to go to 77 without orph

User Image StockloManiac Posted - 10 hours ago

$IRNT Massive potential in $ORPH. $77 to $3 🤔🤔

User Image OOOOOOOOOOH Posted - 10 hours ago

$CRTX This is $ORPH 2.0. Could easily do 3x from here. Do your research folks. No wonder new PTs from etablished firms are at $30+

User Image StockloManiac Posted - 10 hours ago

$IRNT want to see a shorted stock ?? Look at $ORPH THATS THE NEXT PLAY

User Image Sandy001 Posted - 11 hours ago

$ORPH “The stock market is a no-called-strike game. You don’t have to swing at everything – you can wait for your pitch.” SIR WARREN BUFFETT

User Image Kikimora35 Posted - 12 hours ago

$ORPH don’t worry unless that bag with Gold patience

User Image Barrera0 Posted - 12 hours ago

$ORPH bags are getting heavier!!😂

User Image bullfirst Posted - 13 hours ago

$ORPH no hope on this one…

User Image Bosin Posted - 13 hours ago

$ORPH LOL, even hardcore bear lost interest to post on a red day.

User Image bullfirst Posted - 13 hours ago

$ORPH let’s go to $2 and let me avg down

User Image Sandy001 Posted - 13 hours ago

$PHUN let’s go to the moon🚀🚀🚀🚀🚀💸 $ORPH

User Image yoonito Posted - 13 hours ago

$ORPH what goes up must come down. vice versa?

User Image Motomoto86 Posted - 14 hours ago

$ORPH buying more Thanks

User Image DJay89 Posted - 14 hours ago

$ORPH creating new 52w lows 😉

User Image bullfirst Posted - 14 hours ago

$ORPH ok this dump like bad news coming?

User Image RealRJ Posted - 14 hours ago

$ORPH NOT EVER

User Image bullfirst Posted - 14 hours ago

$ORPH not today…

User Image RandomGuyOnInternet Posted - 14 hours ago

$ORPH what do we have to look forward to here?

Analyst Ratings
B of A Securities Underperform Mar 30, 21